Deutsche Bank AG Has $23.70 Million Holdings in Insmed, Inc. (NASDAQ:INSM)

Deutsche Bank AG cut its holdings in Insmed, Inc. (NASDAQ:INSM) by 36.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 310,618 shares of the biopharmaceutical company’s stock after selling 178,348 shares during the quarter. Deutsche Bank AG’s holdings in Insmed were worth $23,697,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. lifted its stake in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares during the period. Elequin Capital LP acquired a new position in Insmed in the fourth quarter valued at approximately $28,000. NBC Securities Inc. acquired a new position in Insmed in the first quarter valued at approximately $49,000. Versant Capital Management Inc lifted its stake in Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 590 shares during the period. Finally, Signaturefd LLC lifted its stake in Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 325 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on INSM shares. Bank of America boosted their price objective on Insmed from $94.00 to $109.00 and gave the company a “buy” rating in a report on Wednesday, June 11th. UBS Group restated a “buy” rating and set a $133.00 price objective (up previously from $124.00) on shares of Insmed in a report on Friday, August 8th. Morgan Stanley restated an “equal weight” rating and set a $126.00 price objective on shares of Insmed in a report on Wednesday. Leerink Partners boosted their price objective on Insmed from $100.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, June 10th. Finally, Citigroup upgraded Insmed to a “buy” rating in a report on Tuesday, June 10th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.86.

Insmed Trading Up 0.7%

Shares of Insmed stock opened at $122.87 on Thursday. The stock has a fifty day simple moving average of $101.43 and a 200 day simple moving average of $83.19. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $123.42. The company has a market capitalization of $25.97 billion, a P/E ratio of -21.52 and a beta of 0.95. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%. The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same quarter last year, the company posted ($1.94) EPS. The company’s quarterly revenue was up 18.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the company’s stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the transaction, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider owned 89,407 shares of the company’s stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 527,515 shares of company stock worth $49,787,158 in the last quarter. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.